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Stability and function of adult vasculature is
sustained by Akt/Jagged1 signalling axis in
endothelium
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The signalling pathways operational in quiescent, post-development vasculature remain
enigmatic. Here we show that unlike neovascularization, endothelial Akt signalling in
established vasculature is crucial not for endothelial cell (EC) survival, but for sustained
interactions with pericytes and vascular smooth muscle cells (VSMCs) regulating vascular
stability and function. Inducible endothelial-speciﬁc Akt1 deletion in adult global Akt2KO mice
triggers progressive VSMC apoptosis. In hearts, this causes a loss of arteries and arterioles
and, despite a high capillary density, diminished vascular patency and severe cardiac
dysfunction. Similarly, endothelial Akt deletion induces retinal VSMC loss and basement
membrane deterioration resulting in vascular regression and retinal atrophy. Mechanistically,
the Akt/mTOR axis controls endothelial Jagged1 expression and, thereby, Notch signalling
regulating VSMC maintenance. Jagged1 peptide treatment of Akt1DEC;Akt2KO mice and
Jagged1 re-expression in Akt-deﬁcient endothelium restores VSMC coverage. Thus, sustained
endothelial Akt1/2 signalling is critical in maintaining vascular stability and homeostasis,
thereby preserving tissue and organ function.
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D
espite the progress in understanding developmental
mechanisms, the signalling pathways operational in post-
natal life remain elusive. Gene knockouts (KOs) controlling
basic cellular responses result in early lethality or functional
compensation by other related molecules, thereby precluding or
obscuring detailed analysis of their consequences1–4. While some
signalling circuits are shared by developmental and postnatal
processes5, recent studies using new inducible and/or tissue-speciﬁc
KO models revealed that the functions of many key signalling
molecules in development are distinct and even opposite from that
in postnatal life6,7. In particular, this applies to vasculature, which,
once formed during embryonic development, remains relatively
quiescent throughout adulthood. With rare exceptions, postnatal
expansion or disturbance of vasculature is triggered by injury or
pathological conditions8. Therefore, the pathways mediating
dynamic cellular responses in development, such as vascular cell
differentiation, migration and proliferation, are expected to be
dormant during adulthood. An essential part of vasculature is
endothelium, a crucial interface between circulating blood and
tissues, and interference with its survival or integrity leads to
pathologies ranging from acute thrombosis to uncontrolled
inﬂammation8. Thus, it is critical for healthy endothelium to
remain quiescent and unperturbed.
One main pathway activated during growth, cell proliferation
and migration is Akt signalling, which integrates growth factor,
cytokine and metabolic stimuli, and is essential for
development9,10. Akt mutations in Drosophila or substantial
reductions in Akt activity, such as those observed in double KO of
Akt1 and Akt2 in mice, result in lethality11,12. In endothelium,
Akt signalling is activated by growth factor stimulation during
angiogenesis9,13. While no vascular defects were observed in
ubiquitous single Akt2KO9, Akt1KO mice displayed increased
endothelial apoptosis under pathological conditions14 and a series
of abnormalities during vascular development and angiogenesis,
some of which were highly context dependent13–19. Overall, the
exact functions of Akt signalling in vasculature remain
under debate13, mostly due to the difﬁculties in interpreting
global AktKO phenotypes, which affected diverse functions of
multiple cell types, ranging from endothelial and mural cells to
inﬂammatory cells14,20, platelets17 and ﬁbroblasts18,21,22, involved
in neovascularization. Since Akt is positioned at the crossroads of
numerous signalling pathways with a number of positive and
negative feedback loops9,23–26, thus controlling diverse and even
opposite functions, it is impossible to predict the tissue-speciﬁc
responses to Akt ablation27,28. A similar scenario applies to one of
the upstream activators of Akt, PI3K signalling, and its role in
vasculature. While most studies conclude that this signalling
axis is absolutely critical for vascular development29–31,
interference with PI3K signalling either diminishes30 or
promotes neovascularization32–34.
Since the Akt pathway is often hyperactivated in proliferating
and metastatic cancer cells10, several potent Akt inhibitors are
currently in clinical trials in patients with advanced
malignancies35–37. However, the consequences of Akt signalling
ablation and the nature of observed adverse effects in humans
remain poorly understood35,37,38. The question whether the Akt
pathway, typically associated with cell transformation and
proliferation, is essential for normal cells existing in a relatively
quiescent state, exempliﬁed by endothelium, remains open.
Accordingly, to determine whether Akt signalling remains
important for established vasculature and to understand the
Akt-dependent circuits operational in adults, we induced Akt1
deletion in endothelial cells (ECs) of mature animals (Akt1DEC).
To exclude possible compensation by Akt2, which might affect
total Akt activity39, we also generated double Akt1DEC;Akt2KO
mice. On the basis of the results of developmental studies, one
might predict that the shutdown of Akt activity in any cell type is
likely to lead to excessive apoptosis. It could be anticipated that
disruption of Akt signalling in EC might result in the loss of
endothelial integrity, subsequent thrombosis and sudden death,
similar to the phenotype observed by the disruption of the best
known Akt activator in endothelium, vascular endothelial growth
factor (VEGF)40. We show that EC Akt deletion does not alter EC
survival, but instead leads to the gradual loss of VSMCs due to
diminished Jagged1/Notch signalling. These structural changes in
the vasculature result in impaired vessel perfusion and severe
tissue dysfunction. Thus, Akt signalling is integral in maintaining
tissue function by preserving postnatal vessel integrity.
Results
Endothelial Akt1 deletion triggers vascular regression. Akt1
excision was induced in mature Akt1DEC;Akt2KO and Akt1DEC
mice with wild-type (WT) and Akt2KO mice serving as controls.
As detailed in Methods and in Supplementary Figs 1–3, deletion
was most complete in hearts and retinas resulting in more than
95% ablation of Akt1 and nearly complete deletion of total Akt
activity in endothelium of Akt1DEC;Akt2KO mice.
Surprisingly, Akt shutdown in adult endothelium did not cause
acute events leading to lethality. However, gross examination of
Akt1DEC;Akt2KO and Akt1DEC hearts revealed visibly fewer
and smaller coronary vessels compared with WT and Akt2KO
hearts (Fig. 1a). To further assess the changes in vasculature, we
stained heart sections with CD31 and smooth muscle actin
(SMA) to visualize ECs and mural cells, respectively (Fig. 1b).
After 4 weeks of excision, there was a 43-fold decrease in
the density of large (4100mm) SMAþ blood vessels in
Akt1DEC;Akt2KO hearts compared with both WT and Akt2KO
hearts (Fig. 1c). In Akt1DEC mice, large SMAþ blood vessel
numbers were also slightly decreased compared with WT,
indicating the contribution of both Akt isoforms (Fig. 1b,c).
Surprisingly, there was no loss of ECs, and the density of
small CD31þ capillaries even increased in Akt1DEC;Akt2KO
hearts (Fig. 1b) resulting in 42-fold higher capillary to arteriole
ratios in Akt1DEC;Akt2KO hearts than in WT and Akt2KO
hearts (Fig. 1d). Concurrently, no marked changes were observed
in vasculature of control WT or Akt2KO mice (Fig. 1b–d).
Quantitative analysis revealed that the diameters of SMA-positive
arterioles in hearts were substantially reduced on Akt excision
(Fig. 1e,f).
Microcomputed tomography (microCT) imaging conﬁrmed
the structural changes in arterial vasculature of WT and
Ak1DEC;Akt2KO hearts (Fig. 1g). Analysis of the numbers of
vessels in each diameter bin demonstrated the loss of larger
arteries and arterioles (Fig. 1h). However, the smaller capillaries,
evident by staining, are not perfused by the contrast reagent;
therefore, the capillary increase could not be detected by microCT
(Supplementary Fig. 4). The use of a vasodilator in microCT
experiments conﬁrmed that observed changes in the diameter and
large blood vessel numbers reﬂect vascular remodelling rather
than vasoconstriction. Of note, B30% of Akt1DEC;Akt2KO, but
not WT mice, experience vascular ruptures during perfusion
highlighting their vascular abnormalities. Together, these results
show that endothelial Akt1 ablation does not result in the loss of
endothelium, but induces severe vascular remodelling character-
ized by arteriole loss and increased small capillary density.
Though Akt2 might partially compensate for the loss of Akt1, it is
endothelial Akt1 that is a determining factor in this process.
In parallel, the size and number of cardiomyocytes were
assessed in heart sections. Cardiomyocyte area and perimeter
showed a small but signiﬁcant increase in Akt1DEC;Akt2KO
hearts compared with WT (Supplementary Fig. 5). However, the
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number of cardiomyocytes per ﬁeld was not signiﬁcantly changed
demonstrating that the vascular changes were not due to
alterations in heart size.
To examine the temporal effects of Akt deﬁciency, we
monitored changes in hearts of Akt1DEC;Akt2KO mice without
or 4 and 10 weeks after tamoxifen-induced excision. As evident
from Fig. 2a,b, there was a time-dependent loss of large SMAþ
blood vessels, which resulted in 3-fold lower density of large
arterioles (4100 mm) in the hearts of Akt1DEC;Akt2KO mice but
not in WT and Akt2KO mice after 10 weeks of tamoxifen
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Figure 1 | Vascular abnormalities triggered by Akt1 deletion. (a) Representative images of WT, Akt2KO, Akt1DEC and Akt1DEC;Akt2KO hearts after
tamoxifen treatment for 4 weeks (5 days i.p. tamoxifen injection followed by 3 weeks tamoxifen diet, 8–9 weeks old). Scale bar, 2mm. (b) Representative
images of WT, Akt2KO, Akt1DEC and Akt1DEC;Akt2KO heart sections after 4 weeks of tamoxifen treatment stained for CD31 (red), SMA (green) and DAPI
(blue). Scale bar, 100mm. (c,d) Quantiﬁcation of 4100mm (large) SMAþ vessels per ﬁeld and capillary (CD31þ SMA) to arteriole (CD31þ SMAþ)
ratio represented as mean±s.e.m. (n¼4). (e,f) Quantiﬁcation of the largest and top ﬁve largest cardiac artery diameters measured in the heart sections
represented as mean±s.e.m. (n¼ 5–6). (g) Representative microCT images for WT and Akt1DEC;Akt2KO hearts after 10 weeks of tamoxifen treatment
(5 days of i.p. tamoxifen injection followed by 9 weeks of tamoxifen diet, 14–15 weeks old). (h) Quantiﬁcation of the numbers of vessels within each
diameter bin represented as mean±s.e.m. (n¼ 5–7). *Po0.05, **Po0.01 and ***Po0.005 by one-way analysis of variance (c,d) or Student’s t-test (e–h).
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treatment. Density of CD31þ capillaries displayed an opposite
trend (Fig. 2c) thereby increasing the capillary to large arteriole
ratio by 2.5- and 5.5-fold in Akt1DEC;Akt2KO hearts, 4 and 10
weeks after initiation of Akt1 deletion, respectively (Fig. 2d).
Thus, endothelial Akt1 deletion results in a progressive loss of
larger and mature SMAþ blood vessels, despite the overall high
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Figure 2 | Vascular regression and vascular patency on tamoxifen administration. (a) Representative images of Akt1DEC;Akt2KO 13- to- 14-week-old
mice heart sections stained for CD31 (red), SMA (green) and DAPI (blue) without tamoxifen (TAM), and 4 and 10 weeks (wks) after Akt1 excision (5 days
of i.p. tamoxifen injection followed by 3 or 9 weeks of tamoxifen diet). Scale bar, 100mm. (b–d) Quantiﬁcation of 4100mm (large) SMAþ or CD31þ
vessels per ﬁeld and capillary (CD31þ SMA) to arteriole (CD31þ SMAþ) ratio represented as mean±s.e.m. (n¼4). (e) Representative images of
Akt1DEC;Akt2KO hearts of littermate mice perfused with lectin with and without TAM treatment for 4 weeks. Scale bar, 100mm. (f–i) Quantiﬁcation of
vessel volume per ﬁeld, average vessel volume, large vessel number (41,000 mm3) and leakage area per ﬁeld represented as mean±s.e.m. (n¼ 3–5).
*Po0.05, **Po0.01 and ***Po0.005 by one-way analysis of variance (b–d) or Student’s t-test (f–i).
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density of capillaries. In contrast, lymphatic vasculature in
Akt1DEC;Akt2KO mice was not signiﬁcantly diminished
compared with WT as judged by LYVE1 staining
(Supplementary Fig. 6).
Vascular patency is diminished after Akt1 excision. To further
determine how these changes affect vascular patency of
microvasculature, we perfused Akt1DEC;Akt2KO littermate mice
(without and 4 weeks after excision) with lectin, which penetrates
capillaries and larger blood vessels. Consistent with microCT,
confocal imaging revealed marked changes in functional cardiac
vasculature on Akt deletion (Fig. 2e and Supplementary Movies 1
and 2). EC Akt deletion resulted in a 55% decrease of perfused
vasculature volume (Fig. 2f) and 60% reduction in the average
volume of functional blood vessels (Fig. 2g). As evident from
Fig. 2h, there was a marked loss of large blood vessels
(41,000 mm3 in volume) on tamoxifen treatment. Thus, despite
the high density of small CD31þ capillaries, the volume of patent
or perfused vasculature in hearts was severely diminished.
Increased lectin in the extravascular space (Fig. 2i) indicated
possible vascular leakage in Akt1DEC;Akt2KO mice, which might
be explained by the loss of VSMC. However, no substantial
haemorrhaging was observed in retinas or hearts. Also, the
blood–brain barrier (BBB) and blood–spinal cord barrier were
intact in Akt1DEC;Akt2KO mice (Supplementary Fig. 7), and no
clinical signs of neurological dysfunction, such as abnormal gait
or seizures were observed.
Similar remodelling in patent vasculature was observed in
retinas. As shown in Fig. 3a and Supplementary Movies 3 and 4,
tamoxifen treatment resulted in a 3.3-fold decrease in the average
blood vessel volume (Fig. 3b), which diminished total volume of
perfused vasculature (Fig. 3c). These results were corroborated
with an analysis of SMA and isolectin B4 co-staining in WT,
Akt2KO, Akt1DEC and Akt1DEC;Akt2KO retinas after
tamoxifen treatment (Fig. 3d). Akt1DEC;Akt2KO mice exhibited
a 50% loss of VSMC coverage compared with WT mice, while
changes in Akt2KO and Akt1DEC retinas were not signiﬁcant
(Fig. 3e). Diminished VSMC coverage was more apparent when
Akt excision was induced at P2 during retinal vasculature
development. Figure 3f shows examples of patchy radial
artery SMA staining in Akt1DEC;Akt2KO retinas at P10, in
contrast to complete and smooth VSMC coverage in WT mice.
Quantiﬁcation revealed 50% decrease in VSMC volume in
Akt1DEC;Akt2KO retinas as compared with WT (Fig. 3g).
Vascular deterioration in Akt1DEC;Akt2KO mice was
accompanied by a marked loss of the basement membrane
component, collagen IV (Fig. 3h and Supplementary Movies 5
and 6). The presence of collagen IVþ and isolectin structures
demonstrate areas of vascular regression (Fig. 3h, arrows).
Quantiﬁcation of three-dimensional (3D) images revealed a
3-fold decrease in co-patterning of isolectin and collagen IV in
Akt1DEC;Akt2KO retinas compared with Akt2KO mice (Fig. 3i).
The volume of vasculature with detectable basement membrane
was also diminished by 2.6-fold (Fig. 3i). There was a thinning of
blood vessels in Akt1DEC;Akt2KO retinas compared with
Akt2KO (Fig. 3j). Thus, EC-speciﬁc Akt excision does not affect
endothelium but causes the loss of VSMC coverage, basement
membrane and vascular patency in highly vascularized tissues
such as hearts and retinas.
Loss of VSMCs on endothelial Akt excision. Quantitative
reverse transcription–PCR (RT–PCR) analysis of whole-heart
lysates conﬁrmed the drastic reduction in VSMC marker
expression: Sma, Myh11 and Sm22a, in Akt1DEC;Akt2KO mice
compared with WT, and simultaneous increase in CD31 gene
expression (Fig. 4a). These changes in VSMC differentiation
marker expression were triggered by Akt1 excision (Fig. 4b).
Heart tissue section staining for Myh11 conﬁrmed the loss of this
VSMC differentiation marker in Akt1DEC;Akt2KO hearts at the
protein level (Fig. 4c). There was almost 50% decrease in the ratio
of Myh11þ to CD31þ area in Akt1DEC;Akt2KO hearts
compared with WT (Fig. 4c, right panel). Concurrently, 3D
reconstruction of NG2-, SMA- and isolectin B4-stained 100-mm
heart sections revealed no substantial abnormalities in
associations between pericytes and blood vessels in Akt1DE-
C;Akt2KO mice compared with WT (Supplementary Fig. 8A–C).
No reduction in pericyte numbers was observed either
(Supplementary Fig. 8D–F). Thus, Akt1 KO in EC triggers
progressive loss of VSMC differentiation markers while pericyte
numbers are not affected.
Similar results were obtained in retinas, where quantitative
RT–PCR showed B2-fold decline in Sma in Akt1DEC;Akt2KO
mice, while mice with single Akt1DEC isoform deletion also had
decreased Sma (Fig. 4d), thereby conﬁrming the key role for
endothelial Akt1. Likewise, Akt1 deletion in endothelium was
sufﬁcient to cause reduction in Sm22a and Myh11 expression in
retinas (Fig. 4e,f). This phenotype was recapitulated in mice
treated with Akt inhibitor, MK2206, which blocks both Akt1 and
Akt2 and to a lesser extent, Akt3. Akt inhibition led to decreased
expression of VSMC differentiation markers Sma, Sm22a and
Myh11 in hearts (Supplementary Fig. 9A) and to lesser extent in
retinas (Supplementary Fig. 9B). Likewise, there was a reduction
in average diameter of retinal blood vessels in mice treated with
MK2206 (Supplementary Fig. 9C).
To further understand the mechanisms of VSMC loss in
Akt1DEC;Akt2KO vasculature, we stained heart tissue sections
for cleaved caspase 3. ECs were identiﬁed based on CD31 or
isolectin B4 staining, whereas VSMC was visualized by SMA
staining (Fig. 4g). Notably, most cleaved caspase 3 staining was
localized in the area surrounding CD31þ ECs (Fig. 4g, ii), which
in some cases was also positive for SMA (Fig. 4g, iii). Knowing
that Akt deﬁciency led to VSMC marker loss, ﬁrst being SMA as
early as 4 weeks after initiation of excision, we quantiﬁed cleaved
caspase 3 in the perivascular area immediately adjacent to
CD31þ ECs (Fig. 4h). This analysis revealed B6-fold increased
perivascular cleaved caspase 3 staining in Akt1DEC;Akt2KO
compared with WT hearts 10 weeks after Akt1 excision
(Fig. 4g,h). Simultaneously, cleaved caspase 3 immunoreactivity
in the CD31þ area was minimal and not signiﬁcantly different
between the two groups (Fig. 4h). Cleaved caspase 3 staining
outside of vasculature was moderately increased in Akt1DE-
C;Akt2KO compared with WT hearts, indicating slightly
increased apoptosis of other cells, including cardiomyocytes,
possibly due to the lack of perfusion (Fig. 4h). Thus, Akt1
deletion in endothelium leads to the loss of VSMC markers
followed by apoptosis at the later time points. The process of
vascular regression occurred gradually over the period of 10
weeks without marked increases in tissue hypoxia based on
pimonidazole staining (Supplementary Fig. 10) consistent with
limited cardiomyocyte apoptosis at chosen time points.
Akt1 signalling controls the Jagged1/Notch pathway. Since the
main pathways controlling VSMC differentiation and recruitment
and, possibly, retention involve either the Notch–Jagged1 or
PDGFRb axis, we analysed expression of related genes by
quantitative RT–PCR in heart tissue from WT, Akt2KO,
Akt1DEC and Akt1DEC;Akt2KO mice (Fig. 5). We documented
that EC Akt1 excision triggered a marked reduction in Notch
target expression in hearts (Fig. 5a,b). Indeed, tamoxifen-induced
Akt1 deletion in Akt1DEC;Akt2KO mice caused 49-fold
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decrease in both Hes1 and Hey2 as evidenced by quantitative
RT–PCR of whole hearts with and without tamoxifen treatment
(Fig. 5a). Analysis of at least four hearts per genotype conﬁrmed
that expression of Hes1, Hey2, Dll4 and Notch3 in Akt1DE-
C;Akt2KO hearts was substantially lower than in WT hearts
(Fig. 5b). The changes in Pdgfrb (also a Notch target41) were
substantially milder and did not reach statistical signiﬁcance
(Fig. 5b). This was further conﬁrmed using primary EC isolated
from Akt1DEC;Akt2KO mice. The analysis demonstrated
42-fold decrease in Notch signalling targets Hes1, Hey2,
Notch3, Notch1 and Notch4 in ECs from Akt1DEC;Akt2KO
mice compared with WT controls (Fig. 5c).
Since induced Akt1 deletion is endothelium-speciﬁc, it likely
effects the endothelial components of Notch signalling, for
example, Jagged1, which interact with Notch3 on VSMC to
mediate their retention and differentiation from pericytes42–46.
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Figure 3 | Perfusion and regression of retinas after Akt1 deletion. (a) Representative images of Akt1DEC;Akt2KO retinas of littermate mice (8–9 weeks
of age) perfused with lectin with and without tamoxifen (TAM) treatment for 4 weeks. Scale bar, 100mm. (b,c) Quantiﬁcation of average vessel volume and
vessel volume per ﬁeld represented as mean±s.e.m. (n¼ 3). (d) Representative images of WT, Akt2KO, Akt1DEC and Akt1DEC;Akt2KO whole-mount
retinas after 4 weeks of tamoxifen treatment (8–9 week old mice) stained for SMA (red), isolectin B4 (green) and DAPI (blue). Scale bar, 50 mm.
(e) Quantiﬁcation of per cent SMAþ coverage represented as mean±s.e.m. (n¼ 3). (f) Representative images of WTand three different Akt1DEC;Akt2KO
whole-mount retinas of 10-day neonatal mice after tamoxifen treatment stained for SMA (green) and CD31 (red) demonstrating the various coverage
phenotypes. Scale bar, 200mm. (g) Quantiﬁcation of the SMA coverage volume per ﬁeld represented as mean±s.e.m. (n¼ 3). (h) Representative images
of Akt2KO and Akt1DEC;Akt2KO whole-mount retinas (8- to 9-week-old mice) after 4 weeks of tamoxifen treatment stained for collagen IV (red) and
isolectin B4 (green). The proximal focal plane (top), distal focal plane (bottom) and 3D reconstruction are shown. Arrows demonstrate empty collagen IV
sleeves. Scale bar, 100mm. (i,j) Quantiﬁcations of the percentage of co-patterning, stained vessel volume and thickness of lectinþ vessels represented as
mean±s.e.m. (n¼ 3–4). *Po0.05, **Po0.01 and ***Po0.005 by Student’s t-test (b,c,g–j) or one-way analysis of variance (e).
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Since Jagged1 is expressed on several cell types, including VSMC,
isolated EC were used. Jagged1 gene expression was decreased
42-fold in ECs isolated from Akt1DEC;Akt2KO mice compared
with WT ECs (Fig. 5c). This was translated into changes at the
protein level of Jagged1 in isolated ECs, where Jagged1 level was
dependent on the presence of Akt1 (Fig. 5d and Supplementary
Fig. 16). Akt1 deletion but not Akt2 in ECs resulted in decreased
Jagged1 levels compared with WT ECs. This expression was
further diminished in ECs lacking both Akt isoforms
(Akt1DEC;Akt2KO). As a result, Jagged1 levels in
Akt1DEC;Akt2KO ECs were 4.6-fold lower than in WT ECs
(Fig. 5d and Supplementary Fig. 16). Thus, in WT EC, the main
isoform controlling Jagged1 expression is Akt1. However, in the
absence of Akt1, this function can be performed by Akt2;
therefore, there is an additive effect of Akt2KO on Jagged1 levels
in Akt1-deﬁcient but not WT EC.
Whole-heart immunoblotting conﬁrmed that deletion of
individual Akt isoforms resulted in reduction of Jagged1
in vivo, however, the most marked decrease was observed in
Akt1DEC;Akt2KO hearts (Fig. 5e and Supplementary Fig. 16). As
anticipated, this reduction in Jagged1 led to overall decreased
Notch signalling as evidenced by mRNA and protein expression
of main Notch targets in hearts (Fig. 5b,c,e). Results of
immunoblotting show the gradual decrease in Hes1 levels in
hearts with deletion of single Akt isoforms, and similar to Jagged1
expression, the most severe reduction was observed in Akt1DE-
C;Akt2KO hearts (Fig. 5e and Supplementary Fig. 16). Thus, the
presence of Akt1 in EC may be essential for endothelial Jagged1
expression and the overall Notch signalling in the whole-organ
context. Akt1 deletion in EC triggers a progressive decrease in
Notch signalling in heart tissue, thereby diminishing VSMC
differentiation, survival and vascular patency. The retinal
vasculature development in inducible EC-speciﬁc Jagged1KO is
characterized by reduced vascular branching and diminished
VSMC coverage47. When Akt excision was induced under similar
conditions (at P2), the phenotype of Akt1DEC;Akt2KO
retinal vasculature showed similarities to EC-speciﬁc inducible
Jagged1KO including reduced branching and lack of SMA
staining (Supplementary Fig. 11 and Fig. 3f,g). The loss
of VSMC in Akt1DEC;Akt2KO retinas was also reminiscent of
Notch3 / mice48.
Although Akt has many downstream targets, Akt-mediated
mTOR activation is one of the main determinants in
transcriptional regulation. Thus, to assess the mechanism by
which Akt regulates Jagged1 expression in endothelium, the
components of this pathway were inhibited by AktX for Akt,
rapamycin for mTOR, or LY294002 or wortmannin for PI3
kinase in human umbilical vein ECs (HUVECs). Interference
with the PI3K/Akt/mTOR signalling pathway led to diminished
pAkt and reduced mTOR activity based on p70 S6 levels
(Fig. 5f and Supplementary Fig. 16). The blockade of Akt directly
or by PI3K inhibitors diminished Jagged1 (Fig. 5f). Rapamycin
treatment produced a similar effect demonstrating the involve-
ment of mTOR in regulation of Jagged1 in ECs (Fig. 5f). Further,
inhibition of Akt signalling by AktX or PI3K inhibitors
diminished Jagged1 transcription in both HUVEC and mouse
ECs as evidenced by changes in RNA levels (Fig. 5g,h and
Supplementary Fig. 16). These results show that decreased
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Jagged1 is a direct consequence of interference with Akt/mTOR
pathway in ECs. As expected, inhibition of this pathway led to
markedly diminished expression of the main Notch target, Hey2
(Fig. 5g,h), which, similar to Jagged1, was sensitive to the
treatment with DAPT, a Notch pathway inhibitor (Fig. 5g).
Similar effects on Jagged1 and Hey2 were achieved by inhibition
of mTOR (Fig. 5h). During differentiation, transcriptional activity
of mTOR pathway often involves p63 and STAT3 (refs 49–51). In
endothelium, the blockade of Akt and mTOR resulted in reduced
p63 levels (Fig. 5g,h). Since STAT3 has been reported to serve as a
transcriptional activator of p63 (ref. 52) and a downstream target
of mTOR49,53, we examined Stat3 expression on Akt inhibition in
endothelium. The mRNA levels of STAT3 were decreased in cells
treated with PI3K, Akt and mTOR inhibitors (Fig. 5g,h),
suggesting that STAT3 might serve as a link connecting Akt/
mTOR activation and p63 expression to induce Jagged1. In
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concert, gene expression of Stat3 and p63 were decreased in ECs
isolated from Akt1DEC;Akt2KO mice compared with WT ECs
(Fig. 5c). Thus, Akt controls Notch signalling by upregulating
Jagged1 expression on EC via mTOR/STAT3/p63 pathway.
Correspondingly, we assessed alterations in Notch downstream
signalling in VSMCs isolated from Akt1DEC;Akt2KO and WT
mice. In Akt1DEC;Akt2KO VSMCs, 65% of Notch signalling
target genes expression was downregulated by more than 1.5-fold
(Supplementary Table 1). These data demonstrate that EC Akt
expression controls Jagged1 surface expression and Notch
signalling in VSMCs.
Jagged1 induction rescues VSMC loss and vascular patency. To
demonstrate that VSMC loss in Akt1DEC;Akt2KO mice is caused
by downregulation of Jagged1 we sought to correct the defects
caused by Akt deﬁciency with Jagged1 peptide administration.
Injections of Jagged1, but not scrambled control peptide increased
VSMC marker expression (Sma, Sm22a and Myh11) in hearts of
Akt1DEC;Akt2KO mice (Fig. 6a).
To further demonstrate that the rescue is EC-dependent,
isolated EC from Akt1DEC;Akt2KO mice was treated with either
control or Jagged1-encoding retrovirus. Jagged1-overexpressing
or control Akt1DEC;Akt2KO ECs containing matrigels were
injected subcutaneously in WT mice on tamoxifen and were
sectioned to examine changes in vascular maturation (Fig. 6b).
Quantiﬁcation of isolectinþ cells demonstrated that an equal
number of ECs was present in matrigels (Fig. 6c). Jagged1
overexpression in Akt1DEC;Akt2KO ECs resulted in a signiﬁcant
increase in the coverage of SMAþ VSMCs on the vasculature
(Fig. 6d). In addition, Jagged1 overexpression, conﬁrmed by gene
expression of Jagged1 and Hes1, increased Sma expression in
matrigels (Fig. 6e). Thus, in two different experiments, Jagged1
rescued the deﬁciencies in VSMC retention caused by Akt
shutdown. Importantly, Jagged1 re-expression in Akt-deﬁcient
ECs substantially improved vascular patency as indicated by the
increased amount of blood in matrigel plugs containing
Akt1DEC;Akt2KO ECs treated with Jagged1 retrovirus compared
with Akt1DEC;Akt2KO ECs infected with control retrovirus
(Supplementary Fig. 12). These data indicate that Akt regulation
of Jagged1 levels on ECs is responsible for the maintenance of
VSMC coverage of vasculature and, as a result, vascular patency.
Endothelial Akt1 deletion causes organ dysfunction. Dimin-
ished Jagged1/Notch signalling in Akt null ECs and subsequent
deterioration of vasculature led to severe organ dysfunction in
Akt1DEC;Akt2KO mice. Echocardiography 4 weeks post
initiation of Akt1 ablation revealed that EC-speciﬁc deletion of
Akt1 in Akt2KO mice caused marked cardiac dysfunction
(Fig. 7a–e) characterized by marked reduction in percentages of
fractional shortening (Fig. 7d) and ejection fraction (Fig. 7e),
whereas no substantial effect was observed in the absence of
single isoforms (Fig. 7a–e). Correspondingly, Akt1DEC;Akt2KO
hearts were dilated (Fig. 7b) and displayed increased heart/body
weight ratio (Supplementary Fig. 13). The deleterious remodelling
was observed only in Akt1DEC;Akt2KO but not in Akt2KO mice
despite prolonged treatment with tamoxifen (10 weeks;
Supplementary Fig. 14). Most marked cardiac dysfunction was
observed in Akt1DEC;Akt2KO but not in Akt1DEC mice
suggesting that in many tissues Akt2 isoform might compensate
for the lack of Akt1. In the absence of Akt2, however, inducible
deletion of Akt1 in endothelium, which is a minor cell type in
heart tissue, causes severe cardiac dysfunction suggesting the
requirement of Akt1/2 signalling in endothelial homeostasis.
Likewise, detrimental changes in blood supply to retina
resulted in marked consequences. As shown in Fig. 7f, there
was a substantial loss of cellularity of all layers in the retina in
Akt1DEC;Akt2KO mice compared with WT and Akt2KO mice
resulting in tissue regression and retinal dystrophy. Thickness of
inner and outer nuclear retinal layers was decreased by 80% and
70%, respectively, in Akt1DEC;Akt2KO but not in Akt2KO mice
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compared with WT (Fig. 7g,h). Changes in single Akt1DEC mice
were modest but still detectable (Fig. 7g,h). Vascular regression
and tissue dystrophy were also evident in Akt1DEC;Akt2KO
retinas stained for CD31, Ki-67 (to visualize proliferating cells)
and 4,6-diamidino-2-phenylindole (DAPI) in comparison with
WT and Akt2KO retinas (Fig. 7i). Cell proliferation was
diminished by 77% and 30% in Akt1DEC;Akt2KO and Akt1DEC,
respectively, compared with WT mice while no changes were
observed in Akt2KO mice (Fig. 7j). Thus, loss of VSMC and
vascular regression triggered by Akt shutdown in endothelium
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caused severe degeneration of retinas. The problems with eyes in
Akt1DEC;Akt2KO but not in WT mice were associated with
changes in size and position of the eye ball, inﬂammation and
ulcerations, possibly due to scratching (Supplementary Fig. 15).
Together, shutdown of endothelial Akt signalling causes gradual
loss of VSMC differentiation markers and VSMC coverage
followed by their apoptosis, severe vascular remodelling and
regression of patent vasculature leading to tissue degeneration
and organ failure.
Discussion
The main ﬁndings are the following: (1) inducible endothelial
Akt1 deletion on the Akt2KO background resulted in nearly
complete ablation of Akt signalling in endothelium. Surprisingly,
this did not affect EC survival, but led to a progressive loss of
VSMC differentiation markers, and loss of arterial vasculature
VSMC coverage followed by VSMC apoptosis at later time points.
This led to structural changes in coronary vasculature, impaired
vascular patency in the heart and severe cardiac dysfunction. (2)
Likewise, Akt1 deletion in retinal endothelium resulted in the loss
of VSMC and collagen IV coverage of blood vessels, vascular
remodelling and vascular patency reduction leading to retinal
dystrophy. (3) The main phenotypes of Akt KOs were
recapitulated using Akt inhibitor in vitro and in vivo. (4) Analysis
of gene expression in the absence of Akt1 in vitro and in vivo
revealed marked decreases in Notch targets, including Hes1 and
Hey2, which was due to a diminished expression of a Notch
ligand, Jagged1 on ECs. (5) Akt activity in adult endothelium is
required for sustained Jagged1/Notch signalling and vascular
stability and homeostasis as Jagged1 administration rescued
VSMC loss in vivo.
Together, our study demonstrates that Akt’s function in
established vasculature is distinct from development. While
global double Akt1/Akt2KO in mice is lethal11, ablation of both
Akt1 and Akt2 in adult tissue did not cause massive cell death or
apoptosis. Instead, inducible Akt KO reduced endothelial Jagged1
expression and perturbed endothelial interactions with VSMC,
emphasizing that endothelium is not simply a barrier between
blood and vessel wall, but a guardian of vasculature stability. This
demonstrates that the function of Akt signalling in fully
developed quiescent tissue is distinct from that during either
developmental or postnatal vascular growth or remodelling. In
developing vasculature, initial endothelial growth and sprouting is
followed by Jagged1/Notch dependent pericyte differentiation
into VSMC45, which cover and stabilize vessels further expanding
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arterial vasculature44,48. Cellular and molecular events triggered
by Akt shutdown results in reduction of Jagged1/Notch
signalling, loss of VSMC markers (de-differentiation) followed
by their apoptosis, culminating in vascular thinning and
regression, resembling a gradual reversal of vascular
development. Under conditions of quiescence, the Akt pathway
functions as a coordinator of heterologous cell–cell interactions
and vascular stability.
Shutdown of Akt signalling in endothelium, a minor cell type in
heart tissue compared with cardiomyocytes, ﬁbroblasts and blood
cells, resulted in marked vascular regression and severe organ
dysfunction as early as 4 weeks after induction. This emphasizes a
key role for endothelium in supporting patent vasculature,
tissue perfusion and, as a result, performance of an organ with
high energy and oxygen demands, such as the heart. Thus,
nearly complete suppression of Akt signalling for prolonged time
in endothelium alone might lead to vascular defects and
insufﬁcient tissue perfusion causing organ failure. Most potent
Akt inhibitors demonstrated a similar extent of Akt inhibition in
both the malignant and normal tissues of cancer patients (the
median decrease was B89% based on pSer473)35. Administration
of Akt inhibitor in vivo caused similar changes in VSMC
recapitulating the phenotype of Akt KOs. Interestingly, various
Akt inhibitors cause an unexpectedly wide range of adverse effects,
ranging from skin rash to haematological complications, and
importantly, including cardiac failure35,37,38,54. Altogether, this
raises a question whether complete or nearly complete suppression
of Akt signalling for a prolonged period of time will be safe in
normal tissues, especially tissues exposed to the high
concentrations of the drug, such as endothelium. At the very
least, one can expect that inhibition of Akts in endothelium might
lead to destabilization of existing vasculature, which, in turn, might
affect neovascularization responses, such as wound healing or
angiogenesis in tumours.
It remains unclear what upstream signalling is essential for this
vascular stabilization function of Akts in endothelium. One could
speculate that Akt activity in quiescent EC might be sustained, at
least in part, by autocrine VEGF–VEGFR2 signalling in
endothelium, which was essential for vascular homeostasis40.
However, disruption of VEGF autocrine loop in endothelium led
to endothelial apoptosis, microvascular infarctions and sudden
death40, a phenotype clearly distinct from that observed in our
study. Likewise, the direct involvement of another important
upstream activator of Akt, PI3K signalling, in vascular
stabilization is difﬁcult to predict. Results of inducible ablation
of PI3K signalling in vasculature are not available and ubiquitous
KOs of selected PI3K isoforms exhibit rather severe
phenotypes30–32, which are more complex and diverse that the
one in our study. However, our ﬁnding that the lack of Akt
signalling results in vascular destabilization can help to
understand why neovascularization processes in ubiquitous
Akt1 and PI3K KO mice as well as in vitro results might be so
context dependent that they appear controversial16–18,31,32,34.
Our analysis revealed that deletion of Akt1 led to decreased
expression of a Notch ligand and target, Jagged1, on ECs. Jagged1
on endothelium is required for induction of Notch3 in mural cells
by an autoregulatory loop43,55. Increased Notch, in turn, increases
Jagged1 expression thereby resulting in ampliﬁcation of the
signal56,57. Thus, reduction in Jagged1 might be sufﬁcient to cause
diminished Notch signalling in the context of the entire heart.
Indeed, we show that deletion of Akt1 in EC of
Akt1DEC;Akt2KO mice led to marked changes in the
expression of the main Notch targets, exempliﬁed by Hes1,
Hey2 and Dll4, in whole-heart tissue. Notch signalling is a well-
established regulator of vascular maturation and arteriogenesis
during development42,44,56. Expression of Notch targets58,
especially Hey2, is essential not only for coronary vascular
maturation during development59 but also for overall cardiac
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development and function58. Despite the overwhelming evidence
that Jagged1/Notch signalling is a master regulator of mural cell
differentiation and vascular maturation in development, little is
known regarding the consequences of Notch inhibition in adults.
The role of Notch was shown in the context of either
neoangiogenesis44,60–63 or remodelling63 processes triggered by
injury63,64 rather than in the vascular stability and homeostasis.
Literature analysis60,65,66 allows speculation that interference with
Jagged1/Notch signalling in adult vasculature will lead to
substantial vascular destabilization similar to inducible Akt
KOs. Observed reduction in Dll4 combined with diminished
Jagged 1 in Akt1DEC;Akt2KO mice might further augment the
observed defects in VSMC coverage as suggested by a recent
study63. More direct comparison of the consequences of Akt EC
KOs to that of Jagged1 EC KO47,63 in retinal model revealed a
number of similarities, including reduced branching and, most
importantly, severe lack of VSMC coverage. However, the
phenotype of EC-speciﬁc Jagged1KO is considerably milder
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Figure 7 | Functional tissue consequences from Akt ablation. (a) Representative echocardiography for WT, Akt2KO, Akt1DEC and Akt1DEC;Akt2KO mice
after 4 weeks of tamoxifen treatment. Scale bar, 100mm. (b–e) LVEDD, LVESD, percentage of fractional shortening and percentage of ejection fraction
calculated from echocardiography representing mean±s.e.m. (n¼4–6). (f) Representative images of WT, Akt2KO, Akt1DEC and Akt1DEC;Akt2KO retinas
after tamoxifen treatment for 4 weeks stained with haematoxylin and eosin. INL, inner nuclear layer; ONL, outer nuclear area; OPL, outer plexiform layer; OS,
inner and outer photoreceptor segment; RPE, retinal pigment epithelium layer and choroid. (g,h) Quantiﬁcation of the thickness of the outer and inner nuclear
layers represented as mean percentage decrease from control±s.e.m. (n¼ 3–4). (i) Representative images of WT, Akt2KO, Akt1DEC and Akt1DEC;Akt2KO
retinas after tamoxifen treatment for 4 weeks stained for CD31 (red), the proliferation marker Ki-67 (green) and DAPI (blue). Scale bar, 100mm.
(j) Quantiﬁcation of the intensity of Ki-67 staining as mean percentage of control±s.e.m. (n¼ 2). *Po0.05, **Po0.01 and ***Po0.005 by one-way analysis
of variance.
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than one of its upstream regulator, Akt, due to the existence of
other, possibly interdependent pathways of vascular maturation,
including Angiopoietin2 as recently described by Ju et al.67
Likewise, KOs of signalling molecules upstream of the same
pathway may display more severe phenotypes. Indeed, the defects
in vascular maturation during angiogenesis in mice expressing
inactive form of p110alpha isoform of PI3K (ref. 32) are even
more pronounced than in Akt KO. However, it is possible that the
observed phenotype with expression of inactive PI3K including
increased vascular density and reduced pericyte coverage could be
due to alterations in Jagged1 downstream of Akt activation.
Together, it is possible that imbalance of Jagged1/Notch
signalling resulting from Akt inhibition might be a contributing
factor to hyper branching and immature vascular phenotypes
observed in neovascularization models exempliﬁed by tumour
angiogenesis17,32,68. Thus, our results demonstrate that
endothelial Akt pathway in fully developed vasculature is
essential for the maintenance of Notch ligand expression,
subsequent Notch signalling and vascular stability.
In sum, we show that a complete shutdown of Akt signalling in
endothelium of adult mice has unexpected yet detrimental
consequences on mature vasculature in several tissues and cardiac
function suggesting the essential role for this pathway in vascular
homeostasis.
Methods
Experimental animals. Mice with tamoxifen-inducible Cre recombinase
expression under the VE-Cadherin promoter (Cdh5(PAC)-CreERT2) on a C57BL/6
background were generated by Ralf H. Adams69. These mice were crossed with
Akt1ﬂ/ﬂ mice (generated by Dr Nissim Hay; C57BL/6 background)70 to generate
Cdh5(PAC)-CreERT2;Akt1ﬂ/ﬂ (Akt1DEC). These mice were then crossed with
Akt2 / (Akt2KO; from Dr Nissim Hay; C57BL/6 background) mice to generate
Cdh5(PAC)-CreERT2;Akt1ﬂ/ﬂ;Akt2 / (Akt1DEC;Akt2KO). C57BL/6 (WT)
mice were used as controls. To generate reporter mice, Cdh5(PAC)-CreERT2;
Akt1ﬂ/ﬂ;Akt2 / (Akt1DEC;Akt2KO) were crossed with mT/mG reporter
mice (from Jackson Labs). In the resultant mT/mG;Cdh5(PAC)-CreERT2;
Akt1ﬂ/ﬂ;Akt2 / (mT/mG;Akt1DEC;Akt2KO) mice, all tissues express the
red membrane targeted (m)-tomato. However, in tamoxifen-treated mT/mG;
Akt1DEC;Akt2KO mice, where the Cre recombinase gene is expressed, the ECs
express the membrane targeted green ﬂuorescent protein (m-GFP) on their surface.
Thus, the Cre recombinase expression induced by tamoxifen can be easily tracked
in these mice indicating where the Akt1 gene has been deleted. Age- and
gender-matched mice were used for all experiments. No differences were noted
between male and female mice in cardiac function or heart weight to body weight
ratios. Mice were subdivided into experimental groups based on the tissues being
collected and interventions performed. All animal procedures were performed in
accordance with the Institutional Animal Care and Use Committee of the
Cleveland Clinic guidelines. Experiments were terminated, at the latest, 10 weeks
after tamoxifen treatment as requested by the veterinarian due to inﬂammation and
ulcerations developing on the eyes of Akt1DEC;Akt2KO mice.
Tamoxifen treatment. For intraperitoneal (i.p.) injections, tamoxifen (Sigma) was
dissolved in 100% ethanol and then diluted in corn oil to a ﬁnal concentration of
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20mgml 1. Four- or ﬁve-week-old mice were injected daily with 4 ml per g body
weight for 5 days. After injection, mice were placed on tamoxifen diet (Harlan
Tekland) until experimental termination (either 3 or 9 additional weeks) resulting
in a total of 4 or 10 weeks of tamoxifen treatment and mice aged 8–9 weeks after 4
weeks of tamoxifen or 14–15 weeks after 10 weeks of tamoxifen treatment. Con-
tinuous tamoxifen diet after injections resulted in a greater decrease in total Akt as
judged by immunoblotting, especially at the later time points (10 weeks after
initiation of excision). This regimen of tamoxifen treatment resulted in successful
excision of Akt1 in genomic DNA as demonstrated by the presence of the
B300-bp band (Supplementary Fig. 1). This treatment schedule was chosen based
on monitoring the total Akt levels in tissue lysates (heart, spleen and liver as shown
in Supplementary Figs 2 and 3). We did not observe a substantial effect of
tamoxifen on vascular parameters in either WT, Akt2KO or Cre( )Akt1DEC;
Akt2KO mice. In all experiments, Akt2KO and Cre( )Akt1DEC;Akt2KO
exhibited similar phenotypes, therefore, either of these controls are shown. For cell
culture experiments, treatment with 60 ngml 1 VEGF (R&D Systems) was used to
induce VE-Cadherin expression in adult murine lung ECs. After 3 days, 1 mM
4-hydroxytamoxifen (Sigma) was added to cultures to induce genetic deletion of
Akt1 in isolated ECs for 3 days. Cultures were then used in subsequent
experiments.
Tamoxifen regimen rationale. The in vivo tamoxifen regimen was optimized for
maximal deletion of Akt1 in the ECs of adult tissues. The 5 days of i.p. injection
was found to be minimally sufﬁcient to induce excision of Akt1 in genomic DNA
with minimal impact on the health of the animals. After the initial injections, the
concern was that the excision in adult tissues could be mosaic, as Cdh5 expression
is decreased after development in most tissues. This mosaic excision would result in
endothelium containing both WT and Akt1DEC cells, and one cell type could have
a growth advantage leading to a selection of one cell type over the other. To prevent
this from occurring, we maintained mice on a tamoxifen diet throughout
experimental manipulation to ensure continued deletion of Akt1 in adult
endothelium. This tamoxifen regimen of 5 days i.p. injection followed by at least 3
weeks of tamoxifen diet (4 weeks of tamoxifen treatment in total) was shown to
efﬁciently reduce Akt1 expression in tissues, with hearts displaying the highest
decrease in Akt1 levels (Supplementary Fig. 3).
To determine that the EC Akt1 deletion was the main cause of all phenotypic
changes, we utilized two experimental approaches with controls. First, we used
separate murine genotypes: WT, Akt1DEC, Akt2KO and Akt1DEC;Akt2KO mice,
all treated with 4 weeks of tamoxifen to account for any side effects of tamoxifen
treatment. As the excision does not occur in WT or Akt2KO mice, any changes
seen in these mice would be a side effect of tamoxifen. Second, we used
Akt1DEC;Akt2KO littermates separated into groups: one with and one without 4
weeks of tamoxifen treatment. This experimental approach allowed us to directly
compare the effects of EC Akt1 deletion due to tamoxifen in the same genotype
using age- and gender-matched littermates.
The in vitro tamoxifen regimen was again based on a loss of Cdh5 expression in
adult tissues. Lung tissues from mice after 4 weeks of tamoxifen treatment showed
a very small decrease in Akt1. Thus, we treated all isolated lung ECs with
60 ngml 1 VEGF for 3 days to induce Cdh5 expression. Then, cells were treated
with 1 mM tamoxifen for 3 days to induce deletion of Akt1, which was conﬁrmed
by immunoblotting (Supplementary Fig. 2).
KOs of Akts in endothelium. To visualize Cre recombinase expression in adult
tissues, Cdh5(PAC)-CreERT2;Akt1ﬂ/ﬂ;Akt2 / (Akt1DEC;Akt2KO) were crossed
with mT/mG reporter mice. The highest levels of tamoxifen-induced Cre
recombinase activity were found in heart and retinal tissues (Supplementary
Fig. 2A). The percentage of mGþ and CD31þ ECs was490% in heart and480%
in retinas (Supplementary Fig. 2B). In ECs isolated directly from tamoxifen-treated
hearts, gene expression of Akt1 was decreased 495% (Supplementary Fig. 2C). In
isolated lung ECs tamoxifen decreased total Akt levels by435% in Akt1DEC cells
and by 480% in Akt1DEC;Akt2KO cells (Supplementary Fig. 2D,E). In most
organs, EC represent a minor cell type (often o5% of all cells), thus, deletion of
endothelial Akt1 alone is not expected to markedly affect total Akt levels in
whole-organ lysates (Supplementary Fig. 3). Immunostaining of matrigel plugs for
CD31 and Akt1 demonstrated that ECs in Akt1DEC;Akt2KO mice do not express
Akt1, while the blood cells retain Akt1 (Supplementary Fig. 2F). However, during
neovascularization in matrigel plugs, ECs representB50% of the total cell content
(Supplementary Fig. 2G), whereas the other 50% are blood and mural cells. Gene
expression analysis revealed that EC Akt1 deletion in Akt1DEC;Akt2KO mice
resulted inB33% reduction of total Akt1 (Supplementary Fig. 2H), since matrigels
are an equal mixture of ECs and non-ECs (Supplementary Fig. 2G) this likely
represents a complete deletion of Akt1 in ECs. Akt2 was below the detection limit
(Supplementary Fig. 2H). Thus, excision of Akt1 in ECs in vivo was complete.
The changes in Akt levels were detectable in whole-heart lysates where Akt deletion
led to B40% decrease in Akt1 and 40% and 30% reduction in phospho-Akt
(T308) and pan-Akt, respectively, in Akt1DEC;Akt2KO mice compared with WT
mice, whereas Akt2 was absent (Supplementary Fig. 3C). Importantly, no
compensatory changes in the levels of remaining Akt isoform, Akt3 were detected
(Supplementary Fig. 3).
Endothelial cell isolation. Lungs were isolated and digested in 3mgml 1
collagenase–dispase mixture for 4 h. Digested tissues were strained and recovered
murine lung endothelial cells were plated on 10 mgml 1 ﬁbronectin in DMEM
supplemented with 10% FBS, 90 mgml 1 heparin sulfate and 50 ngml 1
endothelial cell growth supplement. Once conﬂuent, murine lung endothelial cells
were puriﬁed by positive selection using anti-CD31 (BD Pharmigen)-coated Dynal
beads (Invitrogen) and used in subsequent experiments after tamoxifen treatment.
Hearts were isolated and digested in 3mgml 1 collagenase–dispase mixture for
4 h. Digested tissues were strained and recovered ECs were puriﬁed by positive
selection using anti-CD31 (BD Pharmigen)-coated Dynal beads (Invitrogen) and
used in subsequent experiments directly after isolation.
Immunoblotting. ECs were lysed in RIPA buffer containing 1mM protease
inhibitors. Hearts were homogenized and lysed in NP-40 lysis buffer containing
aprotinin and leupeptin hemisulfate salt (Sigma). Samples were separated by
electrophoresis and transferred to a polyvinylidene diﬂuoride membrane. Proteins
were detected with (1:1,000) antibodies against Akt1, Jagged1, Hes1, GADPH
(all from Santa Cruz Biotechnology), Akt2, Akt3, pan-Akt, phospho-Akt(S473),
phospho-Akt(T308), phospho-S6 (all from Cell Signalling Technologies), p63
(from Genetex), tubulin and b-actin (all from Sigma). Densitometry was performed
using NIH ImageJ. Full scans of western blots are presented in Supplementary
Fig. 16.
Matrigel plug assay. Matrigel (500 ml; BD Biosciences) containing VEGF (250 ng)
was injected subcutaneously (s.c.) into tamoxifen-treated mice during the last week
of diet. Plugs were removed after 7 days and processed for immunoﬂuoresence or
used in quantitative RT–PCR analysis. For experiments with Jagged1 re-expression,
ECs were infected with a retrovirus expressing Jagged1 or a control retrovirus. In
all, 5 105 infected ECs were encapsulated in matrigel containing VEGF and
injected s.c. into tamoxifen-treated WT mice. Plugs were removed after
14 days and processed for immunoﬂuorescence or used in quantitative RT–PCR
analysis.
Immunoﬂuorescence. Hearts, eyes or matrigels were embedded in OCT freezing
medium and sectioned at 7 mm. Sections were then ﬁxed in 4% paraformaldehyde
(PFA) and incubated with primary antibodies raised against CD31 (1:50, BD
Pharmigen), GFP (1:200, Rockland), Akt1 (1:100, Cell Signaling), isolectinB4-
biotin (1:50, Life Technologies), Ki-67 (1:50, Dako), cleaved caspase 3 (1:50, Cell
Signaling), Jagged1 (1:50, SantaCruz), LYVE1 (1:50, Abcam), Myh11 (1:50,
Abcam), NG2 (1:50, Millipore) or anti-SMA (1:100, Abcam). The Akt1 antibody
was tested for speciﬁcity on global Akt1KO tissues and did not show nonspeciﬁc
staining. Tissues were then washed in PBS and exposed to a ﬂuorescently labelled
secondary antibodies (Invitrogen). In addition, antibodies directly conjugated to
ﬂuorophores were used including wheat germ agglutinin-488 (Life Technologies)
and SMA-Cy3 (Sigma). Slides were mounted with VectamountþDAPI (Vector
Labs) and images were taken using either a TCS-SP (Leica) or a ZMZ1000 (Nikon)
microscope. The images were quantiﬁed using ImagePro software (Media
Cybernetics).
For cleaved caspase 3 quantiﬁcation, the estimated area of smooth muscle
surrounding each vessel (B20 mm from the wall of the vessel gauged by shadow in
background staining) was traced, followed by using the ‘clear outside’ function.
Following this, colour channels were split and for each channel, threshold values
were set and area measurements were taken. Area for each vessels cleaved caspase 3
staining was divided by CD31 staining area. Final percentages for vessels from each
heart were then averaged.
Quantitative PCR. For real-time RT–PCR, total RNA from whole eyes, hearts and
implanted matrigel plugs were extracted using the RNeasy Micro kit (QIAGEN,
Valencia, CA), according to the manufacturer’s instructions. Primer sequences
can be found in Supplementary Table 2. The RNA was converted into cDNA using
the Omniscript kit (QIAGEN). 18S mRNA served as a control for relative
quantiﬁcation. For detection and quantiﬁcation, a MyiQ real-time PCR detection
system (Bio-Rad Laboratories) was used. PCR reactions were performed using an iQ
SYBR Green Supermix kit (Bio-Rad Laboratories). Data was analysed by the DDCT
method.
Microcomputed tomography. After 10 weeks of tamoxifen treatment, mice were
anesthetized (100mg ketamine per kg body weight and 10mg xylazine per kg body
weight) and injected with 500Uml 1 heparin followed by saturated potassium
chloride solution. The heart was exposed, catheterized and ﬂushed with saline,
followed by a vasodilator (saline with 1,000U l 1 heparin, 4mgml 1 papaverine
and 1 g l 1 adenosine) and 2% PFA. A 20% bismuth nanoparticle in 5% gelatin
was injected as a contrast agent. Hearts were removed and ﬁxed in 2% PFA. Tissues
from mice were excluded from analysis if the tissue structure was compromised
either due to ruptures of the major blood vessels or a lack of sufﬁcient perfusion.
The vasculature in the heart was scanned with a high-resolution microCT imaging
system (GE eXplore Locus SP, GE Healthcare) with a cone beam-ﬁltered back
projection algorithm, set to a 0.008-mm effective detector pixel size. The microCT
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was operated with 60-kVp X-ray tube voltage, 100-mA tube current, 2,960-ms per
frame, 1 1 detector-binning model, 360, and 0.5 increments per view. This
acquisition resulted in a set of contiguous VFF-formatted images through the entire
heart. Microview Software (GE Healthcare) was used to correct and initially
reconstruct raw data with voxels of dimensions 16 mm 16mm 16mm for
visualization. Then this reconstructed microCT data set was transferred to the
Advanced Workstation (version 4.4; GE Healthcare), different post-processing
techniques were used to process segmentation (separate the arterial system from
the contaminating venous system) and re-batch the reconstructed arterial system
according to the re-orientated central line along the long axis of the left ventricle
using a modiﬁed method for quantiﬁcation. Re-orientation is a critical step for
minimizing the quantitative error (change in the cross-sectional shape of the
vascular tree from oval to circle). Multiplanar reformatting techniques permitted us
to view the data set in transverse, sagittal, coronal and hybrid planes. Detailed
morphometric data on the diameters, area, number of vessels and distributions of
different sized vessels were extracted using modiﬁed software (ImageJ;
National Institutes of Health, Bethesda, MD). Afterwards, distribution of the
relative vessel number was automatically calculated with the built-in algorithm.
The data were expressed as a vascular segmental number, representing the total
number of vessels, of a speciﬁed diameter, counted in total reformatted cross-
sections for the whole heart.
Lectin perfusion. To visualize blood vessels in hearts and retinas, we used lectin
perfusion. Four- to ﬁve-week-old littermates were separated into two groups: one
with and one without tamoxifen treatment for 4 weeks. The now 8- to 9-week-old
littermates were anesthetized (100mg ketamine per kg body weight and 10mg
xylazine per kg body weight) and injected intravenously with 100mg of
FITC-labelled lectin (Lycopersicon esculentum; Vector Laboratories). After 15min,
hearts were removed and frozen in OCT medium and sectioned at 30 mm.
Meanwhile, retina were collected and ﬁxed with 4% PFA at 4 C overnight. Lectin
staining was visualized using Apollo confocal microscope (Leica). The 3D image
visualization and quantiﬁcation were performed by Volocity software.
Retina isolation and whole-mount staining. Eyes were isolated from adult mice
treated with 4 or 10 weeks of tamoxifen as described or from 10-day-old pups that
were fed tamoxifen from P2 to P6. Eyes were ﬁxed in 4% PFA and then the retinas
dissected out. For isolectin B4 staining, retinas were permeabilized in 0.5% Triton
X-100/1% BSA/PBS for 2 h. For all staining, retinas were incubated with primary
antibodies anti-CD31 (1:50), anti-collagen type IV (1:100, Abcam), anti-GFP (1:200),
anti-SMA (1:100) or isolectin B4 (1:50) followed by secondary antibodies at 1:1,000
dilution. Staining was visualized using confocal microscopy (Leica TSC SP2).
HUVEC treatment. HUVEC cells (a kind gift from Dr DiCorleto) were serum
starved and then treated with 10 or 50mM AktX (Calbiochem), 10 or 50nM rapa-
mycin (LC Laboratories), 10 or 50mM LY294002 (Cell Signaling Technologies),
20 uM DAPT (N-[(3,5-Diﬂuorophenyl)acetyl]-L-alanyl-2-phenyl]glycine-1,1-dime-
thyl ester or 100 or 500 nM Wortmannin (Sigma-Aldrich) inhibitors for 15min or
24 h. Cells were then lysed for immunoblotting or RNA was isolated using the
Qiagen RNeasy kit.
Jagged1 peptide treatment. Mice at 21 days of age were treated for 5 days of
tamoxifen i.p. followed by 3 weeks of tamoxifen diet. During the last 2 weeks, mice
were injected s.c. daily with 25mg g 1 Jagged1 (CDDYYYGFGCNKFCRPR) or
scrambled (RCGPDCFDNYGRYKYCF) peptide (New England Peptides). Mice
were then killed and heart and eyes were collected for quantitative RT–PCR.
Echocardiography. Cardiac function was assessed in mice after 4 weeks of
tamoxifen diet (B8–9 weeks of age). In vivo heart function was assessed using a
Vivid 7 ultrasound machine (GE Medical) equipped an il3L linear probe operated
at 14MHz. Mice were imaged in a conscious state at a room temperature of 73 F
and with decreased ambient lighting while held by an experienced handler in a
supine left decubitus position. Mice were placed on an adjustable platform
equipped with echocardiograph electrodes to monitor heart and respiration rates.
The heart was imaged in the two-dimensional mode in the parasternal long and
short-axis views with a depth setting of 1.0 cm and at a frame rate ofZ275 frames
per s. Left ventricular (LV) area was measured from short-axis views at papillary
muscle levels, and an M-mode image was obtained at a sweep speed of
200mm s 1. Diastolic LV wall thickness, systolic LV wall thickness, LV end-
diastolic dimension (LVEDD), and LV end-systolic chamber dimension (LVESD)
were measured. All measurements were done from leading edge to leading edge
according to American Society of Echocardiography guidelines. The percentage of
LV fractional shortening (FS) was calculated as follows: FS¼ (LVEDD LVESD)/
LVEDD.
BBB permeability. BBB permeability was assessed using sodium-ﬂuorescein (NaF)
(Sigma), a low-molecular mass molecule (376Da), to detect ﬂuid-phase shifts
between the circulation and central nervous system. Brieﬂy, mice received 100 ml of
10% NaF in PBS intraperitoneally and cardiac blood was collected 10min later.
Mice were transcardially perfused with 10ml of PBS, and spinal cord and brain
removed. Each tissue was weighed, homogenized in PBS using a TissueLyser
(Qiagen) and centrifuged at 14,000g for 2min. A volume of 500 ml of clariﬁed
supernatant was added to 500ml of 15% trichloroacetic acid (Sigma) and
centrifuged at 10,000g for 10min. A volume of 125ml of 5 N NaOH (Sigma-
Aldrich) was added to 500 ml of the supernatant and NaF content measured on a
SpectraMax Mz (Molecular Devices) microplate reader using standards ranging
from 125 to 4,000 mg. NaF in spinal cord or brain was normalized to sera NaF
content using the formula: (mg ﬂuorescence brain tissue per mg of protein)/(mg
ﬂuorescence sera per ml of blood). Data are expressed as fold increases in NaF in
the spinal cord or brain with levels from WT-treated mice set at 1.
VSMC isolation. Smooth muscle cells were isolated from aortic outgrowths.
Aortae will be collected from mice, cleaned and the intimal layer removed. The
aortae were then minced and placed into dishes. After B2 weeks, smooth muscle
cells had migrated onto the dish and aortic explants were removed. Smooth muscle
cells were further subcultured and used in the following experiments.
Quantitative PCR arrays. Total RNA was isolated from smooth muscle cells using
the Qiagen RNeasy kit and cDNA was synthesized using the Qiagen RT2 First
Strand kit. Real-time PCR was performed using Qiagen RT2 Proﬁler PCR Array kit
for Mouse Notch Signaling Targets and measured on a Bio-Rad myIQ2 iCycler.
Data were analysed by the DDCT method using the SABiosciences PCR Array Data
analysis tools to calculate fold change increased expression or decreased expression
in Akt1DEC samples compared with WT.
Akt inhibition. Mice at 21 days of age were treated orally three times per week
with 120mg kg 1 MK2206 (SantaCruz Biotech) in 30% capitsol (Cydex
Pharmaceuticals) for 2 weeks. Mice were then killed and heart and eyes were
collected for quantitative RT–PCR.
Statistical analysis. Student’s t-test analysis or one-way analysis of variance
analysis with Newman–Keuls post-test were used to determine statistical
signiﬁcance using GraphPad Prism 5.0 software. Error bars represent the s.e.m. of
experiments. *Po0.05, **Po0.01 and ***Po0.005. Experiments were repeated at
least three times with 4–6 mice per genotype.
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